title: Oxaliplatin and ototoxicity: is it really safe for hearing?
abstract: OBJECTIVE
  Oxaliplatin is an effective and widely used chemotherapeutic agent in the treatment of many solid tumors. The most common side effects are peripheral neuropathy, gastrointestinal toxicity, and neutropenia. There have been some case reports about ototoxicity with oxaliplatin, but no clinical trials. In this trial, we explored whether or not oxaliplatin has ototoxic effects.
  
  
  METHODS
  A total of 18 patients, 14 with colorectal cancer and 4 with pancreatic cancer, were included in this study. Four patients (22%) were treated with a capecitabine and oxaliplatin (CapeOx) regimen, and 14 patients (78%) were treated with fluorouracil, leucovorin, and oxaliplatin (FOLFOX-6). Patients' pretreatment and posttreatment hearing levels were assessed with high-frequency audiometry and otoacoustic emission tests.
  
  
  RESULTS
  The median time between the first and the last oxaliplatin doses was 3.2 months (range: 2-7 months). There was no hearing loss in tests conducted for both ears of patients at frequencies of 500, 1000, 2000, 4000, 6000, 8000, 12,000, and 16,000 Hz. There was no difference between the pretreatment and posttreatment otoacoustic emission tests.
  
  
  CONCLUSIONS
  Oxaliplatin is a reliable agent in terms of ototoxicity.
authors.affiliation: Department of Ear, Nose, and Throat, Cumhuriyet University, Sivas, Turkey. salimyucekbb@hotmail.com
authors.forename: Salim
authors.initials: S
authors.lastname: Yüce
authors.forename: Mehmet Metin
authors.initials: MM
authors.lastname: Seker
authors.forename: Sema
authors.initials: S
authors.lastname: Koç
authors.forename: Ismail Onder
authors.initials: IO
authors.lastname: Uysal
authors.forename: Turgut
authors.initials: T
authors.lastname: Kaçan
authors.forename: Mehtap
authors.initials: M
authors.lastname: Doğan
authors.forename: Mansur
authors.initials: M
authors.lastname: Doğan
authors.forename: Nalan Akgül
authors.initials: NA
authors.lastname: Babacan
authors.forename: Saadettin
authors.initials: S
authors.lastname: Kiliçkap
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D000069287:Capecitabine; D015331:Cohort Studies; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D034381:Hearing Loss / Q000139:chemically induced* / Q000175:diagnosis; D006320:Hearing Tests; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077150:Oxaliplatin; D010190:Pancreatic Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000069287:Capecitabine; D002955:Leucovorin; D005472:Fluorouracil